Sanofi (NASDAQ:SNY) Shares Purchased by Quantinno Capital Management LP

Quantinno Capital Management LP increased its position in Sanofi (NASDAQ:SNY - Free Report) by 69.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 167,320 shares of the company's stock after acquiring an additional 68,444 shares during the quarter. Quantinno Capital Management LP's holdings in Sanofi were worth $8,070,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Barclays PLC increased its stake in shares of Sanofi by 107.5% in the third quarter. Barclays PLC now owns 639,772 shares of the company's stock worth $36,869,000 after buying an additional 331,445 shares during the period. Pines Wealth Management LLC purchased a new position in shares of Sanofi during the fourth quarter valued at approximately $247,000. Fifth Third Wealth Advisors LLC grew its position in Sanofi by 27.3% during the 4th quarter. Fifth Third Wealth Advisors LLC now owns 5,459 shares of the company's stock valued at $263,000 after purchasing an additional 1,170 shares during the last quarter. Park Avenue Securities LLC grew its position in Sanofi by 14.3% during the 4th quarter. Park Avenue Securities LLC now owns 68,982 shares of the company's stock valued at $3,327,000 after purchasing an additional 8,615 shares during the last quarter. Finally, Cohen Investment Advisors LLC lifted its stake in Sanofi by 3.9% during the 4th quarter. Cohen Investment Advisors LLC now owns 8,271 shares of the company's stock valued at $399,000 after acquiring an additional 310 shares during the period. 14.04% of the stock is currently owned by institutional investors.

Sanofi Price Performance

Shares of SNY stock traded up $0.31 during trading hours on Wednesday, hitting $53.20. 543,316 shares of the company's stock were exchanged, compared to its average volume of 2,369,955. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The firm has a market cap of $134.39 billion, a P/E ratio of 21.35, a P/E/G ratio of 1.01 and a beta of 0.55. The firm has a 50 day moving average of $53.15 and a two-hundred day moving average of $51.88. Sanofi has a fifty-two week low of $45.80 and a fifty-two week high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The business had revenue of $10.41 billion during the quarter, compared to analysts' expectations of $9.79 billion. During the same period in the prior year, the business posted $1.78 EPS. The company's revenue was down 11.0% compared to the same quarter last year. Sell-side analysts forecast that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The company also recently declared an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be given a dividend of $2.0369 per share. This is a positive change from Sanofi's previous annual dividend of $1.48. The ex-dividend date is Friday, May 9th. This represents a yield of 3.1%. Sanofi's payout ratio is 57.14%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. BNP Paribas assumed coverage on shares of Sanofi in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective on the stock. Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a report on Monday, April 28th. The Goldman Sachs Group initiated coverage on shares of Sanofi in a report on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price for the company. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $63.33.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.